About Impel NeuroPharma
Impel NeuroPharma is a company based in Seattle (United States) founded in 2008. Impel NeuroPharma has raised $126.83 million across 19 funding rounds from investors including KKR, NIH and Norwest Venture Partners. The company has 158 employees as of December 31, 2022. Impel NeuroPharma offers products and services including Trudhesa and POD Technology. Impel NeuroPharma operates in a competitive market with competitors including MannKind Corp, OptiNose, CraniUS, Alexza and Qnovia, among others.
- Headquarter Seattle, United States
- Employees 158 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Impel Pharmaceuticals Llc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$126.83 M (USD)
in 19 rounds
-
Latest Funding Round
$7.5 M (USD), Debt – Conventional
Mar 12, 2021
-
Investors
KKR
& 7 more
-
Employee Count
158
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Impel NeuroPharma
Impel NeuroPharma offers a comprehensive portfolio of products and services, including Trudhesa and POD Technology.
Nasal spray for acute migraine treatment with or without aura.
Proprietary system for optimized intranasal drug absorption.
People of Impel NeuroPharma
Unlock access to complete
Unlock access to complete
Funding Insights of Impel NeuroPharma
Impel NeuroPharma has successfully raised a total of $126.83M across 19 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $7.5 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 19
- Last Round Debt – Conventional — $7.5M
-
First Round
First Round
(19 Jan 2010)
- Investors Count 8
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar, 2021 | Amount | Debt – Conventional - Impel NeuroPharma | Valuation |
investors |
|
| Dec, 2018 | Amount | Series D - Impel NeuroPharma | Valuation | KKR , Norwest Venture Partners | |
| Dec, 2016 | Amount | Series C - Impel NeuroPharma | Valuation |
investors |
Investors in Impel NeuroPharma
Impel NeuroPharma has secured backing from 8 investors, including venture fund and institutional investors. Prominent investors backing the company include KKR, NIH and Norwest Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are invested in by this private equity firm.
|
Founded Year | Domain | Location | |
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Founded Year | Domain | Location | |
|
Venture capital and private equity firm
|
Founded Year | Domain | Location |
Investments & Acquisitions by Impel NeuroPharma
Financial Statements - Impel NeuroPharma
Impel Neuropharma Comparisons
Competitors of Impel NeuroPharma
Impel NeuroPharma operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, OptiNose, CraniUS, Alexza and Qnovia, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Developer of small-molecule drugs
|
|
| domain | founded_year | HQ Location |
Developer of smart devices for nasal drug delivery
|
|
| domain | founded_year | HQ Location |
Drug delivery systems for brain diseases and disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of products for the treatment of acute and intermittent conditions
|
|
| domain | founded_year | HQ Location |
Inhaled drug delivery devices are developed for pharmaceuticals.
|
Frequently Asked Questions about Impel NeuroPharma
Impel NeuroPharma was founded in 2008 and raised its 1st funding round 2 years after it was founded.
Impel NeuroPharma is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Impel NeuroPharma is a funded company, having raised a total of $126.83M across 19 funding rounds to date. The company's 1st funding round was a Series C of $21M, raised on Jan 19, 2010.
As of Dec 31, 2022, the latest employee count at Impel NeuroPharma is 158.
Impel NeuroPharma was founded in 2008 in Seattle, United States. Intranasal drug delivery technology is developed by the company for central nervous system diseases. Non-invasive Precision Olfactory Delivery (POD) nasal devices are utilized to create therapies targeting Alzheimers, migraine, and other CNS conditions. Various drugs, including biologics, are enabled for delivery directly to the brain through this approach. Operations focus on biotechnology within the pharmaceutical sector.
Impel NeuroPharma's top competitors include MannKind Corp, OptiNose and CraniUS.
Impel NeuroPharma offers Trudhesa and POD Technology.
Impel NeuroPharma has 8 investors. Key investors include KKR, NIH, Norwest Venture Partners, Vivo Capital, and 5AM Ventures.